Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors.

Molecular differences between cancerous and healthy tissue have become key targets for novel therapeutics specific to tumor receptors. However, cancer cell receptor expression can vary within and amongst different tumors, making strategies that can quantify receptor concentration in vivo critical for the progression of targeted therapies. Recently a dual-tracer imaging approach capable of providing quantitative measures of receptor concentration in vivo was developed. It relies on the simultaneous injection and imaging of receptor-targeted tracer and an untargeted tracer (to account for non-specific uptake of the targeted tracer). Early implementations of this approach have been structured on existing "reference tissue" imaging methods that have not been optimized for or validated in dual-tracer imaging. Using simulations and mouse tumor model experimental data, the salient findings in this study were that all widely used reference tissue kinetic models can be used for dual-tracer imaging, with the linearized simplified reference tissue model offering a good balance of accuracy and computational efficiency. Moreover, an alternate version of the full two-compartment reference tissue model can be employed accurately by assuming that the K1s of the targeted and untargeted tracers are similar to avoid assuming an instantaneous equilibrium between bound and free states (made by all other models).

[1]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[2]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[3]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[4]  Tayyaba Hasan,et al.  Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. , 2010, Academic radiology.

[5]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[6]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  J. Arrowsmith Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[8]  Vasilis Ntziachristos,et al.  In vivo investigation of breast cancer progression by use of an internal control. , 2009, Neoplasia.

[9]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[10]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[11]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[12]  Christopher H Contag,et al.  Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. , 2009, Biophysical journal.

[13]  Walter H Backes,et al.  Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. , 2005, Radiology.

[14]  Jason R. Gunn,et al.  In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging , 2012, Molecular Imaging and Biology.

[15]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[16]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  Rakesh K. Jain,et al.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors , 1990, Cancer and Metastasis Reviews.

[18]  Robert B. Innis,et al.  Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  D L Alexoff,et al.  A Strategy for Removing the Bias in the Graphical Analysis Method , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Tayyaba Hasan,et al.  Imaging targeted-agent binding in vivo with two probes. , 2010, Journal of biomedical optics.

[22]  M. Korc,et al.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Tayyaba Hasan,et al.  Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. , 2012, Journal of biomedical optics.

[24]  Christopher H Contag,et al.  Microscopic Delineation of Medulloblastoma Margins in a Transgenic Mouse Model Using a Topically Applied VEGFR-1 Probe. , 2012, Translational oncology.

[25]  S. Kety The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[26]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[27]  I. Lax,et al.  Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. , 1993, Biochemistry.

[28]  T. Hasan,et al.  Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors , 2012, Physics in medicine and biology.

[29]  J. Arrowsmith Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[30]  Brian W. Pogue,et al.  High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.

[31]  Vesna Sossi,et al.  Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging , 2010, Synapse.

[32]  Greg M Thurber,et al.  A mechanistic compartmental model for total antibody uptake in tumors. , 2012, Journal of theoretical biology.

[33]  Hans Olsson,et al.  A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635 , 2006, NeuroImage.

[34]  Jean Logan,et al.  The Use of Alternative Forms of Graphical Analysis to Balance Bias and Precision in PET Images , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.